Clinical significance of abcb1 in acute ...
Type de document :
Article dans une revue scientifique: Article original
DOI :
PMID :
URL permanente :
Titre :
Clinical significance of abcb1 in acute myeloid leukemia: a comprehensive study
Auteur(s) :
Boyer, Thomas [Auteur]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer (JPArc) - U1172
Gonzales, Fanny [Auteur]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer (JPArc) - U1172
Barthelemy, Adeline [Auteur]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer (JPArc) - U1172
Marceau-Renaut, Alice [Auteur]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 [JPArc]
Peyrouze, Pauline [Auteur]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer (JPArc) - U1172
Guihard, Soizic [Auteur]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 [JPArc]
Lepelley, Pascale [Auteur]
Service d'Hématologie Cellulaire [Lille]
Plesa, Adriana [Auteur]
Service d’Hématologie [Centre Hospitalier Lyon Sud - HCL]
Nibourel, Olivier [Auteur]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer (JPArc) - U1172
Delattre, Carole [Auteur]
Wetterwald, Marc [Auteur]
Pottier, Nicolas [Auteur]
IMPact de l'Environnement Chimique sur la Santé humaine (IMPECS) - EA 4483
Impact de l'environnement chimique sur la santé humaine - ULR 4483 [IMPECS]
Plantier, Isabelle [Auteur]
Botton, Stephane De [Auteur]
Institut Gustave Roussy [IGR]
Dombret, Herve [Auteur]
Université Paris Diderot - Paris 7 [UPD7]
Berthon, Celine [Auteur]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer (JPArc) - U1172
Preudhomme, Claude [Auteur]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer (JPArc) - U1172
Roumier, Christophe [Auteur]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer (JPArc) - U1172
Cheok, Meyling [Auteur]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer (JPArc) - U1172
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 [JPArc]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer (JPArc) - U1172
Gonzales, Fanny [Auteur]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer (JPArc) - U1172
Barthelemy, Adeline [Auteur]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer (JPArc) - U1172
Marceau-Renaut, Alice [Auteur]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 [JPArc]
Peyrouze, Pauline [Auteur]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer (JPArc) - U1172
Guihard, Soizic [Auteur]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 [JPArc]
Lepelley, Pascale [Auteur]
Service d'Hématologie Cellulaire [Lille]
Plesa, Adriana [Auteur]
Service d’Hématologie [Centre Hospitalier Lyon Sud - HCL]
Nibourel, Olivier [Auteur]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer (JPArc) - U1172
Delattre, Carole [Auteur]
Wetterwald, Marc [Auteur]
Pottier, Nicolas [Auteur]
IMPact de l'Environnement Chimique sur la Santé humaine (IMPECS) - EA 4483
Impact de l'environnement chimique sur la santé humaine - ULR 4483 [IMPECS]
Plantier, Isabelle [Auteur]
Botton, Stephane De [Auteur]
Institut Gustave Roussy [IGR]
Dombret, Herve [Auteur]
Université Paris Diderot - Paris 7 [UPD7]
Berthon, Celine [Auteur]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer (JPArc) - U1172
Preudhomme, Claude [Auteur]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer (JPArc) - U1172
Roumier, Christophe [Auteur]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer (JPArc) - U1172
Cheok, Meyling [Auteur]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer (JPArc) - U1172
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 [JPArc]
Titre de la revue :
Cancers
Nom court de la revue :
Cancers (Basel)
Numéro :
11
Pagination :
1323
Date de publication :
2019-09-06
ISSN :
2072-6694
Mot(s)-clé(s) :
ABCB1
acute myeloid leukemia
prognosis
gene expression
drug resistance
acute myeloid leukemia
prognosis
gene expression
drug resistance
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
ABCB1 is a member of the ATP binding cassette transporter family and high ABCB1 activity is considered as a poor prognostic factor in acute myeloid leukemia (AML) treated with intensive chemotherapy, its direct relation ...
Lire la suite >ABCB1 is a member of the ATP binding cassette transporter family and high ABCB1 activity is considered as a poor prognostic factor in acute myeloid leukemia (AML) treated with intensive chemotherapy, its direct relation with drug resistance remains unclear. We evaluated ABCB1 activity in relation with clinical parameters and treatment response to standard chemotherapy in 321 patients with de novo AML. We assessed multiple clinical relationships of ABCB1 activity—ex vivo drug resistance, gene expression, and the ABCB1 inhibitor quinine were evaluated. ABCB1 activity was observed in 58% of AML and was linked to low white blood cell count, high expression of CD34, absence of FLT3-ITD, and absence of mutant NPM1. Moreover, ABCB1 activity was associated with worse overall- and event-free survival. However, ABCB1 activity did not directly lead to ex vivo drug resistance to anthracyclines. We found that ABCB1 was highly correlated with gene expressions of BAALC, CD34, CD200, and CD7, indicating that ABCB1 expression maybe a passenger characteristic of high-risk AML. Furthermore, ABCB1 was inversely correlated to HOX cluster genes and CD33. Thus, low ABCB1 AML patients benefited specifically from anti-CD33 treatment by gemtuzumab ozogamicin in addition to standard chemotherapy. We showed prognostic importance of ABCB1 gene expression, protein expression, and activity. Furthermore, ABCB1 was not directly linked to drug resistance, ABCB1 inhibition did not improve outcome of high ABCB1 AML patients and thus high ABCB1 may represent a passenger characteristic of high-risk AML .Lire moins >
Lire la suite >ABCB1 is a member of the ATP binding cassette transporter family and high ABCB1 activity is considered as a poor prognostic factor in acute myeloid leukemia (AML) treated with intensive chemotherapy, its direct relation with drug resistance remains unclear. We evaluated ABCB1 activity in relation with clinical parameters and treatment response to standard chemotherapy in 321 patients with de novo AML. We assessed multiple clinical relationships of ABCB1 activity—ex vivo drug resistance, gene expression, and the ABCB1 inhibitor quinine were evaluated. ABCB1 activity was observed in 58% of AML and was linked to low white blood cell count, high expression of CD34, absence of FLT3-ITD, and absence of mutant NPM1. Moreover, ABCB1 activity was associated with worse overall- and event-free survival. However, ABCB1 activity did not directly lead to ex vivo drug resistance to anthracyclines. We found that ABCB1 was highly correlated with gene expressions of BAALC, CD34, CD200, and CD7, indicating that ABCB1 expression maybe a passenger characteristic of high-risk AML. Furthermore, ABCB1 was inversely correlated to HOX cluster genes and CD33. Thus, low ABCB1 AML patients benefited specifically from anti-CD33 treatment by gemtuzumab ozogamicin in addition to standard chemotherapy. We showed prognostic importance of ABCB1 gene expression, protein expression, and activity. Furthermore, ABCB1 was not directly linked to drug resistance, ABCB1 inhibition did not improve outcome of high ABCB1 AML patients and thus high ABCB1 may represent a passenger characteristic of high-risk AML .Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
CNRS
Université de Lille
Université de Lille
Collections :
Date de dépôt :
2022-02-02T10:24:11Z
2022-11-09T08:50:51Z
2022-11-09T08:50:51Z
Fichiers
- cancers-11-01323-v2.pdf
- Version éditeur
- Accès libre
- Accéder au document